<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052048</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-AS-2019</org_study_id>
    <nct_id>NCT04052048</nct_id>
  </id_info>
  <brief_title>Active Surveillance SNEP Assay Registry Trial for Prostate Cancer</brief_title>
  <official_title>A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoCell MDX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoCell MDX</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, prospective active surveillance registry trial assessing the performance of a&#xD;
      non-invasive blood test for indolent prostate cancer disease management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll 600 men who are currently on or are candidates for active surveillance&#xD;
      as treatment management for their prostate cancer and are or will be scheduled for a repeat&#xD;
      biopsy. A blood sample will be collected and undergo an immunogenomic assay to be compared to&#xD;
      their repeat biopsy results. Subjects will then be followed for 10 years with optional serial&#xD;
      testing at the time of their active surveillance protocol repeat biopsy. This study's&#xD;
      hypothesis is based on the association of immunogenomic signatures from peripheral blood CD2&#xD;
      and CD14 cells with aggressive prostate cancer, and that this signature will identify&#xD;
      patients with aggressive prostate cancer from a cohort of patients currently on or are&#xD;
      candidates for active surveillance. By comparing the immunogenomic assay to the repeat biopsy&#xD;
      information we will identify the assay's ability to predict occult aggressive cancer that&#xD;
      would indicate the patient is no longer appropriate for continued active surveillance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Collect performance results on assay's ability to identify occult aggressive disease in active surveillance population.</measure>
    <time_frame>1 year</time_frame>
    <description>Collect information from repeat biopsy including any increase in gleason grade, increase in number of cores positive, and increase in % cross sectional surface area involved by tumor from the repeat biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validate immunogenomic assay's ability to serve as an ongoing, non-invasive tool to monitor patient risk for disease progression as detected by repeat biopsy.</measure>
    <time_frame>10 years</time_frame>
    <description>On an annual basis, collect follow-up frequency data for each patient including optional repeat blood testing, repeat biopsy data, disease management decisions, and disease progression.</description>
  </secondary_outcome>
  <enrollment type="Actual">1130</enrollment>
  <condition>Prostate Cancer Aggressiveness</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Subtraction Normalized Expression of Phagocytes Blood Test</intervention_name>
    <description>Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Three tubes of blood:&#xD;
&#xD;
      Two 8ml CPT One 4ml SST&#xD;
&#xD;
      Prostate Biopsy slides&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men with prostate cancer who are on or are candidates for Active surveillance.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men between 40-80 with at least a 10-year life expectancy who based on previous&#xD;
             prostate biopsy results are either candidates for, or are currently on active&#xD;
             surveillance for prostate cancer.&#xD;
&#xD;
               -  Enrollment may be before or after any confirmatory testing.&#xD;
&#xD;
               -  All active surveillance protocols are accepted (Submission of written protocol&#xD;
                  required with enrollment)&#xD;
&#xD;
               -  No PSA limits&#xD;
&#xD;
               -  Patient agrees to have next surveillance biopsy (specify date or within 3 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Men on watchful waiting i.e. those with less than 10-year life expectancy with no intent&#xD;
        for curative therapy&#xD;
&#xD;
          -  Men with symptoms or rising PSA who have not been proven to have cancer by tissue&#xD;
             biopsy i.e. men with only negative prostate biopsies.&#xD;
&#xD;
          -  Patients with a history of a different cancer (except basal cell carcinoma)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Comprehensive Urology</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Palmer C, Diehn M, Alizadeh AA, Brown PO. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics. 2006 May 16;7:115.</citation>
    <PMID>16704732</PMID>
  </reference>
  <reference>
    <citation>Schmidl C, Renner K, Peter K, Eder R, Lassmann T, Balwierz PJ, Itoh M, Nagao-Sato S, Kawaji H, Carninci P, Suzuki H, Hayashizaki Y, Andreesen R, Hume DA, Hoffmann P, Forrest AR, Kreutz MP, Edinger M, Rehli M; FANTOM consortium. Transcription and enhancer profiling in human monocyte subsets. Blood. 2014 Apr 24;123(17):e90-9. doi: 10.1182/blood-2013-02-484188. Epub 2014 Mar 26.</citation>
    <PMID>24671955</PMID>
  </reference>
  <reference>
    <citation>Hashimoto S, Nagai S, Sese J, Suzuki T, Obata A, Sato T, Toyoda N, Dong HY, Kurachi M, Nagahata T, Shizuno K, Morishita S, Matsushima K. Gene expression profile in human leukocytes. Blood. 2003 May 1;101(9):3509-13. Epub 2003 Jan 9.</citation>
    <PMID>12522010</PMID>
  </reference>
  <reference>
    <citation>Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood. 2008 Aug 15;112(4):935-45. doi: 10.1182/blood-2007-12-077917. Review.</citation>
    <PMID>18684880</PMID>
  </reference>
  <reference>
    <citation>Gutknecht MF, Bouton AH. Functional significance of mononuclear phagocyte populations generated through adult hematopoiesis. J Leukoc Biol. 2014 Dec;96(6):969-80. doi: 10.1189/jlb.1RI0414-195R. Epub 2014 Sep 15. Review.</citation>
    <PMID>25225678</PMID>
  </reference>
  <reference>
    <citation>Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol. 2011 Oct 25;11(11):788-98. doi: 10.1038/nri3087. Review.</citation>
    <PMID>22025056</PMID>
  </reference>
  <reference>
    <citation>Epstein JI. An update of the Gleason grading system. J Urol. 2010 Feb;183(2):433-40. doi: 10.1016/j.juro.2009.10.046. Epub 2009 Dec 14. Review.</citation>
    <PMID>20006878</PMID>
  </reference>
  <reference>
    <citation>Grignon DJ. Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens. Mod Pathol. 2018 Jan;31(S1):S96-109. doi: 10.1038/modpathol.2017.167. Review.</citation>
    <PMID>29297497</PMID>
  </reference>
  <reference>
    <citation>Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo X, Chu KC, Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MH, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25.</citation>
    <PMID>26005866</PMID>
  </reference>
  <reference>
    <citation>Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC; Michigan Urological Surgery Improvement Collaborative. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol. 2015 Jan;67(1):44-50. doi: 10.1016/j.eururo.2014.08.024. Epub 2014 Aug 24.</citation>
    <PMID>25159890</PMID>
  </reference>
  <reference>
    <citation>Cher ML, Dhir A, Auffenberg GB, Linsell S, Gao Y, Rosenberg B, Jafri SM, Klotz L, Miller DC, Ghani KR, Bernstein SJ, Montie JE, Lane BR; Michigan Urological Surgery Improvement Collaborative. Appropriateness Criteria for Active Surveillance of Prostate Cancer. J Urol. 2017 Jan;197(1):67-74. doi: 10.1016/j.juro.2016.07.005. Epub 2016 Jul 14.</citation>
    <PMID>27422298</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

